Covered recipient · General Payments record
HASSAN AWAD ABOUHOULI
Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$13,031.61
138 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10,000.00 | 6 |
| Food and Beverage | $2,930.81 | 131 |
| Travel and Lodging | $100.80 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $10,974.95 | 33 |
| GlaxoSmithKline, LLC. | $482.22 | 29 |
| Regeneron Healthcare Solutions, Inc. | $272.98 | 19 |
| Pulmonx Corporation | $229.11 | 6 |
| GENZYME CORPORATION | $141.79 | 9 |
| BSN Medical Inc | $107.25 | 1 |
| Viatris Specialty LLC | $97.12 | 5 |
| Mallinckrodt Hospital Products Inc. | $89.47 | 3 |
| Amgen Inc. | $68.69 | 4 |
| Insmed, Inc. | $65.61 | 4 |
| Merck Sharp & Dohme LLC | $59.41 | 3 |
| HARMONY BIOSCIENCES LLC | $59.39 | 2 |
| Electromed, Inc. | $56.97 | 5 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $53.17 | 2 |
| Inspire Medical Systems, Inc. | $44.49 | 2 |
| ABBVIE INC. | $38.82 | 2 |
| Verona Pharma, Inc. | $37.50 | 2 |
| United Therapeutics Corporation | $32.47 | 1 |
| Grifols USA, LLC | $27.24 | 1 |
| Actelion Pharmaceuticals US, Inc. | $26.40 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $22.07 | 1 |
| ANI Pharmaceuticals, Inc. | $15.02 | 1 |
| Breas Medical, Inc. | $15.00 | 1 |
| Ethicon Inc. | $14.47 | 1 |
Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
HASSAN AWAD ABOUHOULI
NPI 1366564304 · CMS profile ID 16211
Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease
TULSA, OK
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1366564304?year=2025&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- HASSAN AWAD ABOUHOULI, NPI 1366564304, CMS profile ID 16211. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1366564304?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). HASSAN AWAD ABOUHOULI, NPI 1366564304, CMS profile ID 16211. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1366564304?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- HASSAN AWAD ABOUHOULI, NPI 1366564304, CMS profile ID 16211, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1366564304?year=2025&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
138 matching records · $13,031.61 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–138 of 138.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Pulmonx Corporation | $9.26 | 05/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1199534453 | CMS |
| GlaxoSmithKline, LLC. | $12.03 | 05/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1191656149 | CMS |
| Regeneron Healthcare Solutions, Inc. | $21.44 | 05/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212856014 | CMS |
| GENZYME CORPORATION | $9.30 | 05/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233624370 | CMS |
| Viatris Specialty LLC | $20.81 | 04/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238499261 | CMS |
| Regeneron Healthcare Solutions, Inc. | $5.44 | 04/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212856012 | CMS |
| GlaxoSmithKline, LLC. | $18.51 | 04/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1191803121 | CMS |
| Regeneron Healthcare Solutions, Inc. | $1.21 | 04/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212856010 | CMS |
| Pulmonx Corporation | $21.61 | 04/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1199534449 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.38 | 04/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206841315 | CMS |
| Ethicon Inc. | $14.47 | 04/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1173797006 | CMS |
| GlaxoSmithKline, LLC. | $14.53 | 04/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190653258 | CMS |
| Viatris Specialty LLC | $19.98 | 04/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238497951 | CMS |
| Merck Sharp & Dohme LLC | $18.07 | 04/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238137059 | CMS |
| Insmed, Inc. | $16.54 | 04/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186260675 | CMS |
| Mallinckrodt Hospital Products Inc. | $31.85 | 03/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211945904 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.84 | 03/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207111834 | CMS |
| Insmed, Inc. | $15.98 | 03/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186276256 | CMS |
| GlaxoSmithKline, LLC. | $13.33 | 03/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190430092 | CMS |
| Pulmonx Corporation | $16.96 | 02/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1199534445 | CMS |
| GENZYME CORPORATION | $24.44 | 02/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233624514 | CMS |
| GlaxoSmithKline, LLC. | $20.32 | 02/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1191141236 | CMS |
| GlaxoSmithKline, LLC. | $14.67 | 02/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1191556185 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.31 | 02/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206607079 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.09 | 02/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206373159 | CMS |
| Regeneron Healthcare Solutions, Inc. | $25.11 | 02/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212856006 | CMS |
| Regeneron Healthcare Solutions, Inc. | $2.31 | 02/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212856008 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $32.12 | 01/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222970845 | CMS |
| Regeneron Healthcare Solutions, Inc. | $34.15 | 01/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212856004 | CMS |
| Merck Sharp & Dohme LLC | $22.48 | 01/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238093747 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,850.00 | 01/27/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206396176 | CMS |
| AstraZeneca Pharmaceuticals LP | $23.23 | 01/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206543777 | CMS |
| Verona Pharma, Inc. | $24.03 | 01/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233769207 | CMS |
| AstraZeneca Pharmaceuticals LP | $96.66 | 01/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206725473 | CMS |
| GENZYME CORPORATION | $21.22 | 01/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233624494 | CMS |
| AstraZeneca Pharmaceuticals LP | $116.22 | 01/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206654568 | CMS |
| GlaxoSmithKline, LLC. | $21.16 | 01/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1191348715 | CMS |
| GENZYME CORPORATION | $7.86 | 01/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233624490 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $877,701.96 | 55 |
| PY2024 | Principal investigator | $888,540.64 | 132 |
| PY2023 | Principal investigator | $258,679.75 | 64 |
| PY2022 | Principal investigator | $24,029.37 | 5 |
| PY2021 | Principal investigator | $12,623.79 | 4 |
| PY2020 | Principal investigator | $49,176.01 | 1 |
| PY2019 | Principal investigator | $32,851.62 | 2 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
55 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Genentech, Inc. | $1,250.00 | 12/12/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211620848 |
| Principal investigator 1 | PFIZER INC. | $13,762.00 | 12/11/2025 | Non-covered Recipient Entity Layrek Clinical Research | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA | No dispute reported | 06/30/2026 | 1228725844 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,477.90 | 12/11/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049303 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,995.90 | 12/11/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049305 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,718.70 | 12/11/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049307 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,345.30 | 12/04/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049301 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $19,693.10 | 11/26/2025 | Non-covered Recipient Entity LAYREK CLINICAL RESEARCH | A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO) | No dispute reported | 06/30/2026 | 1185554849 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $7,375.55 | 11/13/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049299 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $10,810.80 | 10/23/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049297 |
| Principal investigator 1 | PFIZER INC. | $1,339.39 | 10/19/2025 | Non-covered Recipient Entity LAYREK CLINICAL RESEARCH | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA | No dispute reported | 06/30/2026 | 1228729399 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,394.60 | 10/14/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049295 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $179.90 | 09/30/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244049309 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,985.80 | 09/17/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049293 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $400.00 | 09/11/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049291 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,319.60 | 08/19/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049289 |
| Principal investigator 1 | Genentech, Inc. | $920.00 | 08/06/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211620834 |
| Principal investigator 1 | Genentech, Inc. | $54.00 | 08/06/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211620843 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $393.00 | 07/25/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049285 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $162.50 | 07/25/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049287 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,319.60 | 07/24/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049283 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,345.30 | 07/18/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049281 |
| Principal investigator 1 | Genentech, Inc. | $4,410.00 | 07/09/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211620830 |
| Principal investigator 1 | Genentech, Inc. | $1,517.00 | 07/02/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211620839 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $14,523.60 | 06/24/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049279 |
| Principal investigator 1 | Genentech, Inc. | $6,804.00 | 06/18/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211620799 |
| Principal investigator 1 | Genentech, Inc. | $1,430.00 | 06/11/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211620823 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,068.80 | 06/05/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049277 |
| Principal investigator 1 | Genentech, Inc. | $5,520.00 | 06/04/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211620827 |
| Principal investigator 1 | Genentech, Inc. | $2,790.00 | 05/28/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211620804 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $68.20 | 05/07/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049313 |
| Principal investigator 1 | Genentech, Inc. | $920.00 | 04/30/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211620808 |
| Principal investigator 1 | Genentech, Inc. | $6,440.00 | 04/25/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211620795 |
| Principal investigator 1 | Genentech, Inc. | $2,036.85 | 04/25/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211620819 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $7,309.90 | 04/24/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049275 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $220,260.45 | 04/23/2025 | Non-covered Recipient Entity LAYREK CLINICAL RESEARCH | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1185554839 |
| Principal investigator 1 | Genentech, Inc. | $920.00 | 04/11/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211620815 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,051.90 | 04/10/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049273 |
| Principal investigator 1 | Genentech, Inc. | $920.00 | 04/04/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211620811 |
| Principal investigator 1 | Genentech, Inc. | $4,600.00 | 03/28/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211620783 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $53,415.00 | 03/26/2025 | Non-covered Recipient Entity LAYREK CLINICAL RESEARCH | Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD | No dispute reported | 06/30/2026 | 1185554847 |
| Principal investigator 1 | Genentech, Inc. | $3,680.00 | 03/21/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211620790 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,034.80 | 03/20/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049271 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $862.40 | 03/13/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049267 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $685.50 | 03/13/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049269 |
| Principal investigator 1 | Genentech, Inc. | $1,840.00 | 03/05/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211620775 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $10,340.20 | 02/27/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049265 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 02/26/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211620786 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $204.60 | 02/21/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049311 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $68,248.00 | 02/12/2025 | Non-covered Recipient Entity Layrek Clinical Research | A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1235996233 |
| Principal investigator 1 | Genentech, Inc. | $5,520.00 | 02/12/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211620779 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $37,303.81 | 01/31/2025 | Non-covered Recipient Entity LAYREK CLINICAL RESEARCH | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations | No dispute reported | 06/30/2026 | 1185554841 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,803.80 | 01/30/2025 | Non-covered Recipient Entity LAYREK MANAGEMENT LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049263 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $53,440.21 | 01/21/2025 | Non-covered Recipient Entity Layrek Clinical Research | A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1235996231 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $113,994.49 | 01/17/2025 | Non-covered Recipient Entity LAYREK CLINICAL RESEARCH | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 | No dispute reported | 06/30/2026 | 1185554845 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $150,995.51 | 01/03/2025 | Non-covered Recipient Entity LAYREK CLINICAL RESEARCH | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler | No dispute reported | 06/30/2026 | 1185554843 |